中文名稱  帕金蛋白抗體規(guī)格 

英文名稱  Anti-Parkin protein/PARK2

別    名 AR JP; E3 ubiquitin protein ligase parkin; FRA6E; LPRS 2; LPRS2; PARK 2; PARK2; Parkinson disease (autosomal recessive juvenile) 2; Parkinson disease protein 2; Parkinson juvenile disease protein 2; PDJ; PRKN 2; PRKN; PRKN2; Ubiquitin E3 ligase PRKN.

產(chǎn)品屬性：

帕金蛋白抗體規(guī)格 濃    度  1mg/1ml

規(guī) 格  0.1ml/100μg 0.2ml/200μg

抗體來源  Rabbit

克隆類型   polyclonal

交叉反應(yīng)   Human, Mouse, Rat, Pig

產(chǎn)品類型   一抗  

研究領(lǐng)域    細胞生物 免疫學(xué) 神經(jīng)生物學(xué)

蛋白分子量  predicted molecular weight: 51kDa 

性    狀   Lyophilized or Liquid

免 疫 原  KLH conjugated synthetic peptide derived from human Parkin protein C-terminus

亞    型  IgG

純化方法   affinity purified by Protein A

儲 存 液   0.01M PBS, pH 7.4 with 10 mg/ml BSA and 0.1% Sodium azide

帕金蛋白抗體規(guī)格 產(chǎn)品應(yīng)用   WB=1:100-500 ELISA=1:500-1000 IP=1:20-100 IHC-P=1:100-500 IHC-F=1:100-500 IF=1:100-500

（石蠟切片需做抗原修復(fù)） 

 not yet tested in other applications.

 optimal dilutions/concentrations should be determined by the end user.  

保存條件  Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C. 

Important Note  This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. 

產(chǎn)品介紹 Parkinson's Disease, the second most common neurodegenerative disease after Alzheimer's Disease, is characterized by the loss of dopaminergic neurons and the presence of Lewy bodies (comprised of alpha synuclein and parkin inclusions). Autosomal Recessive Juvenile Parkinsonism (AR-JP) is a recently described form of Parkinson's Disease that has been linked to a gene that codes for parkin. Parkin, a 52 kDa protein, has a suggested role in the ubiquitin/proteasome pathway for protein degradation. The amino terminus bears sequence homology to ubiquitin while functionally it acts as a RING type ubiquitin protein ligase (E3) that coordinates the transfer of ubiquitin to substrate proteins, thus targeting them for degradation by the proteasome.

Function : Functions within a multiprotein E3 ubiquitin ligase complex, catalyzing the covalent attachment of ubiquitin moieties onto substrate proteins, such as BCL2, SYT11, CCNE1, GPR37, STUB1, a 22 kDa O-linked glycosylated isoform of SNCAIP, SEPT5, ZNF746 and AIMP2. Mediates monoubiquitination as well as 'Lys-48'-linked and 'Lys-63'-linked polyubiquitination of substrates depending on the context. Participates in the removal and/or detoxification of abnormally folded or damaged protein by mediating 'Lys-63'-linked polyubiquitination of misfolded proteins such as PARK7: 'Lys-63'-linked polyubiquitinated misfolded proteins are then recognized by HDAC6, leading to their recruitment to aggresomes, followed by degradation. Mediates 'Lys-63'-linked polyubiquitination of SNCAIP, possibly playing a role in Lewy-body formation. Mediates monoubiquitination of BCL2, thereby acting as a positive regulator of autophagy. Promotes the autophagic degradation of dysfunctional depolarized mitochondria. Mediates 'Lys-48'-linked polyubiquitination of ZNF746, followed by degradation of ZNF746 by the proteasome; possibly playing a role in role in regulation of neuron death. Limits the production of reactive oxygen species (ROS). Loss of this ubiquitin ligase activity appears to be the mechanism underlying pathogenesis of PARK2. May protect neurons against alpha synuclein toxicity, proteasomal dysfunction, GPR37 accumulation, and kainate-induced excitotoxicity. May play a role in controlling neurotransmitter trafficking at the presynaptic terminal and in calcium-dependent exocytosis. Regulates cyclin-E during neuronal apoptosis. May represent a tumor suppressor gene.

Subunit : Forms an E3 ubiquitin ligase complex with UBE2L3 or UBE2L6. Mediates 'Lys-63'-linked polyubiquitination by associating with UBE2V1. Part of a SCF-like complex, consisting of PARK2, CUL1 and FBXW7. Interacts with SNCAIP. Binds to the C2A and C2B domains of SYT11. Interacts and regulates the turnover of SEPT5. Part of a complex, including STUB1, HSP70 and GPR37. The amount of STUB1 in the complex increases during ER stress. STUB1 promotes the dissociation of HSP70 from PARK2 and GPR37, thus facilitating PARK2-mediated GPR37 ubiquitination. HSP70 transiently associates with unfolded GPR37 and inhibits the E3 activity of PARK2, whereas, STUB1 enhances the E3 activity of PARK2 through promotion of dissociation of HSP70 from PARK2-GPR37 complexes. Interacts with PSMD4 and PACRG. Interacts with LRRK2. Interacts with RANBP2. Interacts with SUMO1 but not SUMO2, which promotes nuclear localization and autoubiquitination. Interacts (via first RING-type domain) with AIMP2 (via N-terminus). Interacts with PSMA7 and RNF41. Interacts with PINK1.

Subcellular Location : Cytoplasm, cytosol. Nucleus. Endoplasmic reticulum. Mitochondrion. Note=Mainly localizes in the cytosol. Co-localizes with SYT11 in neutrites. Co-localizes with SNCAIP in brainstem Lewy bodies. Relocates to dysfunctional mitochondria that have lost the mitochondrial membrane potential; recruitment to mitochondria is PINK1-dependent.

Post-translational modifications : Auto-ubiquitinates in an E2-dependent manner leading to its own degradation. Also polyubiquitinated by RNF41 for proteasomal degradation.

S-nitrosylated. The inhibition of PARK2 ubiquitin E3 ligase activity by S-nitrosylation could contribute to the degenerative process in PD by impairing the ubiquitination of PARK2 substrates.

DISEASE : Defects in PARK2 are a cause of Parkinson disease (PARK) [MIM:168600]. A complex neurodegenerative disorder characterized by bradykinesia, resting tremor, muscular rigidity and postural instability. Additional features are characteristic postural abnormalities, dysautonomia, dystonic cramps, and dementia. The pathology of Parkinson disease involves the loss of dopaminergic neurons in the substantia nigra and the presence of Lewy bodies (intraneuronal accumulations of aggregated proteins), in surviving neurons in various areas of the brain. The disease is progressive and usually manifests after the age of 50 years, although early-onset cases (before 50 years) are known. The majority of the cases are sporadic suggesting a multifactorial etiology based on environmental and genetic factors. However, some patients present with a positive family history for the disease. Familial forms of the disease usually begin at earlier ages and are associated with atypical clinical features.

Similarity : Belongs to the RBR family. Parkin subfamily.

Contains 1 IBR-type zinc finger.

Contains 2 RING-type zinc fingers.

Contains 1 ubiquitin-like domain.

Database links : UniProtKB/Swiss-Prot: O60260.2

parkin基因的突變，患者很早就會出現(xiàn)氏癥的，Parkin屬于RBR蛋白家族，與泛素相關(guān)蛋白分解途徑有關(guān)。

實驗流程：

全、新、優(yōu)、品、好四大特點：

帕金蛋白抗體規(guī)格 全：公司提供上萬種產(chǎn)品，涵蓋了生物試劑，elisa試劑盒，標(biāo)準(zhǔn)品，培養(yǎng)基，原裝耗材，抗體、培養(yǎng)基、ATCC細胞等，基本上各種科研所需產(chǎn)品在我司都能找到。

新：產(chǎn)品更新速度較快，基本上每周都有新產(chǎn)品出現(xiàn)。

優(yōu)：產(chǎn)品質(zhì)量好，投訴比較少。

好：我公司具有優(yōu)質(zhì)的技術(shù)團隊，產(chǎn)品一旦售出，實驗過程中遇到困難可提供在線技術(shù)咨詢。使您使用產(chǎn)品時沒有任何的后顧之憂。

技術(shù)外包服務(wù):

★帕金蛋白抗體規(guī)格 分子生物學(xué)：質(zhì)粒抽提、PCR、Q-PCR、RT-PCR、分子生物學(xué)：基因合成、引物合成、基因測序、載體構(gòu)建等

★蛋白工程：原核、哺乳動物蛋白表達系統(tǒng)等

★病毒包裝：腺病毒、慢病毒等

★抗體工程：磁珠分選、病理染色、WB、ELISA、IP、IF、IHC、FACS、Confocal等等

★細胞工程：細胞表型分析(凋亡、增殖、周期、遷移、侵襲、修復(fù)、克隆形成)、細胞培養(yǎng)、細胞膜制備、穩(wěn)定細胞株構(gòu)建、細胞RNAi技術(shù)等等。

正在熱銷的相關(guān)產(chǎn)品：

Anti-p-ERK1/p-MAPK-1/2 /FITC 熒光素標(biāo)記磷酸化原活化蛋白激酶1/2抗體IgGMulti-class antibodies規(guī)格： 0.2ml

Anti-MTL/FITC 熒光素標(biāo)記胃動素抗體IgGMulti-class antibodies規(guī)格： 0.2ml

Rhesus antibody Rh C1orf172 1號染色體開放閱讀框172抗體 規(guī)格 0.2ml

TGF- Beta1 (Ttansforming Growth Factor – Beta1) 轉(zhuǎn)移生長因子–β1(抗原) 0.5mg

HSP70 英文名稱： 熱休克蛋白70抗體 0.1ml

Rhesus antibody Rh RRAGA RAS相關(guān)GTP結(jié)合蛋白A抗體 規(guī)格 0.2ml

Anti-MTL/FITC 熒光素標(biāo)記胃動素抗體IgGMulti-class antibodies規(guī)格： 0.2ml

Anti-Lpin1 protein/FITC 熒光素標(biāo)記Lpin1 抗體IgGMulti-class antibodies規(guī)格： 0.2ml

Anti-phospho-Synapsin I (Ser9) /FITC 熒光素標(biāo)記磷酸化神經(jīng)突觸素1抗體IgGMulti-class antibodies規(guī)格： 0.2ml

Rhesus antibody Rh Adiponectin Receptor 1 脂聯(lián)素受體1抗體 規(guī)格 0.2ml

Rabbit Anti-Goat IgG/Alexa Fluor 555 Alexa Fluor 555標(biāo)記的兔抗羊IgG 0.1ml

GPR48 英文名稱： G蛋白偶聯(lián)受體48抗體 0.1ml

Rhesus antibody Rh Rabbit Anti-chicken IgM/FITC FITC標(biāo)記的兔抗雞IgM 規(guī)格 0.3ml

Anti-phospho-Synapsin I (Ser9) /FITC 熒光素標(biāo)記磷酸化神經(jīng)突觸素1抗體IgGMulti-class antibodies規(guī)格： 0.2ml

EAR3(Human eosinophil-associated ribonuclease A family member 3)ELISA Kit 人嗜酸性相關(guān)之RNA水解酵素家族成員3Multi-class antibodies規(guī)格： 48T

Anti-MUC5AC/Mucin 5AC 胃粘液素抗體Multi-class antibodies規(guī)格： 0.1ml

Rhesus antibody Rh Insulin 抗體 規(guī)格 0.1ml

ACA-IgM(Human anti-cardiolipin antibody IgM) ELISA Kit 人抗心磷脂抗體IgM 96T

Phospho-PDGFRA(Tyr1018) 英文名稱： 磷酸化血小板源性生長因子受體-α抗體 0.1ml

C1D 英文名稱： 核DNA結(jié)合蛋白C1D抗體 0.1ml

Anti-MUC5AC/Mucin 5AC 胃粘液素抗體Multi-class antibodies規(guī)格： 0.1ml

CL-0282HO-8910PM(人高轉(zhuǎn)移細胞)5×106cells/瓶×2

TNFSF11 Others Mouse 小鼠 RANKL / OPGL / TNFSF11 / CD254 人細胞裂解液 (陽性對照)

小鼠頜下腺上皮細胞完全培養(yǎng)基 100mL

L W-3A小鼠皮下結(jié)締組織細胞 L W-3A mice subcutaneous connective tissue cells DMEM培養(yǎng)基+10%FBS

IL1A Protein Mouse 重組小鼠 IL-1 alpha / IL1A / IL1F1 蛋白

P3X63Ag8.653(小鼠細胞) 5×106cells/瓶×2 L6(大鼠成肌細胞)

CL-0278HCCLM3(人高轉(zhuǎn)移細胞)5×106cells/瓶×2

IL17RB Others Mouse 小鼠 IL17BR / IL17RB / IL-17 Receptor B 人細胞裂解液 (陽性對照)

人晶狀體上皮細胞cDNAHLEpiC cDNA

LCC1細胞，人癌細胞 VERO衍生株,SVP細胞 成骨細胞Many types of cells包裝：5 × 105次方(1ml)

TG-905(人腦膠質(zhì)母細胞瘤細胞) 5×106cells/瓶×2

HPMEC Pellet 人肺微內(nèi)皮細胞團塊 > 1 mio.cells 多聚賴氨酸 1 mg/mlPLL

帕金蛋白抗體規(guī)格 CD200 Others Cynomolgus 食蟹猴 CD200 人細胞裂解液 (陽性對照)

平滑肌細胞Many types of cells包裝：5 × 105次方(1ml)

615小鼠滑膜瘤株;ZM755

LTEP-s細胞，人肺鱗癌細胞 小鼠皮膚細胞,JB6-C30細胞 CL-0114Hs 578T(人癌細胞)5×106cells/瓶×2

Tca-8113(人舌鱗癌細胞) 5×106cells/瓶×2

HBdMEC-c 人膀胱微內(nèi)皮細胞(HBdMEC) 500,000cells 皮下脂肪細胞Many types of cells包裝：5 × 105次方(1ml)